Head-to-head · Cost-Efficiency Index
Maves vs Synergy Rx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Maves
Shoppers drawn to aggressive low intro pricing on semaglutide who will confirm the exact charge before checkout.
Visit MavesSynergy Rx
People who want a genuine brand-name route and maximum clinician access, and will accept getting a quote by inquiry.
Visit Synergy RxThe verdict
Maves takes it, leading the Cost-Efficiency Index 76 to 72. Maves (operated by parent company Homera Health) is a men's-health/performance-framed telehealth platform offering compounded semaglutide and tirzepatide plus sermorelin. Synergy Rx still earns a C — People who want a genuine brand-name route and maximum clinician access, and will accept getting a quote by inquiry.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Maves.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Maves | Synergy Rx |
|---|---|---|
| Cost-Efficiency Index | 76/100 | 72/100 |
| Semaglutide / mo | $89/mo (starting dose, compounded) | From $199/mo |
| Tirzepatide / mo | Not disclosed | From $349/mo |
| Semaglutide / yr (modeled) | $1,068 | $2,388 |
| Tirzepatide / yr (modeled) | — | $4,188 |
| Coverage | All 50 states | Not disclosed |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Yes |
| Rank here | #49 | #53 |
Maves
76/100Where the value is
- LegitScript badge displayed on the site
- Publishes the FDA compounded-medication disclaimer
- Low advertised semaglutide entry price ($89-99/mo range)
The tradeoffs
- The homepage shows two different numbers for the same starting semaglutide tier ($89/month vs $99 first month) with no reconciliation — the real ongoing price cannot be confirmed from the public site
- Tirzepatide is listed as an offering but no price is published anywhere reachable on the site, confirmed by direct search
Synergy Rx
72/100Where the value is
- Prescribes FDA-approved brand Wegovy, Ozempic and Mounjaro when clinically appropriate, not compounded only
- Unlimited appointments, unlimited messaging and 24/7 access to a dedicated clinical team
- A $100 welcome credit applied at checkout, and FSA/HSA eligible
The tradeoffs
- Prices are published as bare “Starting at” figures with no billing cycle or term attached, so a full-year cost still cannot be modeled before an inquiry
- At $349/mo tirzepatide sits roughly $100 above the compounded median we track
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.